Imagen de Portada

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection

Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozo...

Descripción completa

Detalles Bibliográficos
Autores Principales: Giraldo, Manuel A., Arevalo-Pinzon, Gabriela, Rojas-Caraballo, Jose, Mongui, Alvaro, Rodriguez, Raul, Patarroyo, Manuel A.
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: 2009
Materias:
Adjuvant
Aluminum hydroxide
Antibody
Chloroquine
Emulsifying agent
Freund adjuvant
Montanide isa720
Protein
Recombinant merozoite surface protein 10
Recombinant protein
Unclassified drug
Adjuvant therapy
Affinity chromatography
Animal experiment
Animal model
Antibody production
Antibody titer
Aotus
Article
Controlled study
Drug antigenicity
Drug efficacy
Drug formulation
Immunity
Immunogenicity
Malaria
Nonhuman
Plasmodium vivax
Priority journal
Protein expression
Protein purification
Schizont
Serum
Vaccination
Animals
Aotus trivirgatus
Freund's adjuvant
Humans
Malaria vaccines
Mannitol
Oleic acids
Protozoan proteins
Recombinant proteins
Adjuvants
Merozoite surface proteins (msps)
Vaccine
protozoan
immunologic
humoral
vivax
Antibodies
Antigens
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23453
https://doi.org/10.1016/j.vaccine.2009.09.046

Internet

https://repository.urosario.edu.co/handle/10336/23453
https://doi.org/10.1016/j.vaccine.2009.09.046

Ejemplares similares